Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next?

Perwein MK, Smestad JA, Warrington AE, Heider RM, Kaczor MW, Maher LJ 3rd, Wootla B, Kunbaz A, Rodriguez M.

Expert Opin Biol Ther. 2018 May;18(5):545-560. doi: 10.1080/14712598.2018.1441284. Epub 2018 Feb 25. Review.


Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis.

Lemus HN, Warrington AE, Denic A, Wootla B, Rodriguez M.

Hum Antibodies. 2017;25(3-4):121-129. doi: 10.3233/HAB-170313.


Human class I major histocompatibility complex alleles determine central nervous system injury versus repair.

Wootla B, Denic A, Watzlawik JO, Warrington AE, Zoecklein LJ, Papke-Norton LM, David C, Rodriguez M.

J Neuroinflammation. 2016 Nov 17;13(1):293.


Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis.

Dasari H, Wootla B, Warrington AE, Rodriguez M.

Int J Phys Med Rehabil. 2016 Aug;4(4). pii: 348. Epub 2016 Jun 23.


A human anti-polysialic acid antibody as a potential treatment to improve function in multiple sclerosis patients.

Watzlawik JO, Painter MM, Wootla B, Rodriguez M.

J Nat Sci. 2015 Aug;1(8). pii: e141.


Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study.

Watzlawik JO, Kahoud RJ, Wootla B, Painter MM, Warrington AE, Carey WA, Rodriguez M.

J Vis Exp. 2016 Jun 29;(112). doi: 10.3791/54139.


A monoclonal natural human IgM protects axons in the absence of remyelination.

Wootla B, Denic A, Warrington AE, Rodriguez M.

J Neuroinflammation. 2016 Apr 28;13(1):94. doi: 10.1186/s12974-016-0561-3.


Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

Mahendra A, Peyron I, Thaunat O, Dollinger C, Gilardin L, Sharma M, Wootla B, Rao DN, Padiolleau-Lefevre S, Boquet D, More A, Varadarajan N, Kaveri SV, Legendre C, Lacroix-Desmazes S.

J Immunol. 2016 May 15;196(10):4075-81. doi: 10.4049/jimmunol.1403005. Epub 2016 Apr 11.


Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M.

Expert Opin Biol Ther. 2016 Jun;16(6):827-839. doi: 10.1517/14712598.2016.1158809. Epub 2016 Mar 10. Review.


Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression.

Watzlawik JO, Wootla B, Rodriguez M.

Curr Pharm Des. 2016;22(8):1049-59. Review.


Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression.

Watzlawik JO, Wootla B, Rodriguez M.

Curr Pharm Des. 2015 Dec 14. [Epub ahead of print]


Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.

Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M.

Mol Neurobiol. 2016 Oct;53(8):5217-28. doi: 10.1007/s12035-015-9436-3. Epub 2015 Sep 26. Review.


Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

Wootla B, Watzlawik JO, Warrington AE, Wittenberg NJ, Denic A, Xu X, Jordan LR, Papke LM, Zoecklein LJ, Pierce ML, Oh SH, Kantarci OH, Rodriguez M.

JAMA Neurol. 2015 Nov;72(11):1346-53. doi: 10.1001/jamaneurol.2015.2188. Review.


A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.

Xu X, Denic A, Jordan LR, Wittenberg NJ, Warrington AE, Wootla B, Papke LM, Zoecklein LJ, Yoo D, Shaver J, Oh SH, Pease LR, Rodriguez M.

Dis Model Mech. 2015 Aug 1;8(8):831-42. doi: 10.1242/dmm.020727. Epub 2015 May 28.


Abbreviated exposure to hypoxia is sufficient to induce CNS dysmyelination, modulate spinal motor neuron composition, and impair motor development in neonatal mice.

Watzlawik JO, Kahoud RJ, O'Toole RJ, White KA, Ogden AR, Painter MM, Wootla B, Papke LM, Denic A, Weimer JM, Carey WA, Rodriguez M.

PLoS One. 2015 May 28;10(5):e0128007. doi: 10.1371/journal.pone.0128007. eCollection 2015.


Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders.

Watzlawik JO, Kahoud RJ, Ng S, Painter MM, Papke LM, Zoecklein L, Wootla B, Warrington AE, Carey WA, Rodriguez M.

J Neurochem. 2015 Sep;134(5):865-78. doi: 10.1111/jnc.13121. Epub 2015 Apr 27.


Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice.

Perschbacher K, Smestad JA, Peters JP, Standiford MM, Denic A, Wootla B, Warrington AE, Rodriguez M, Maher LJ 3rd.

Nucleic Acid Ther. 2015 Feb;25(1):11-9. doi: 10.1089/nat.2014.0515. Epub 2014 Dec 23.


Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis.

Denic A, Wootla B, Zoecklein L, Rodriguez M.

J Neurol Transl Neurosci. 2014 Jan;2(1). pii: 1032.


Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases.

Wittenberg NJ, Wootla B, Jordan LR, Denic A, Warrington AE, Oh SH, Rodriguez M.

Expert Rev Neurother. 2014 Apr;14(4):449-63. doi: 10.1586/14737175.2014.896199. Review.


Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Watzlawik JO, Wootla B, Painter MM, Warrington AE, Rodriguez M.

Expert Rev Neurother. 2013 Sep;13(9):1017-29. doi: 10.1586/14737175.2013.835601. Review.


Polyclonal and monoclonal antibodies in clinic.

Wootla B, Denic A, Rodriguez M.

Methods Mol Biol. 2014;1060:79-110. doi: 10.1007/978-1-62703-586-6_5. Review.


IVIg treatment reduces catalytic antibody titers of renal transplanted patients.

Mahendra A, Peyron I, Dollinger C, Gilardin L, Sharma M, Wootla B, Padiolleau-Lefevre S, Friboulet A, Boquet D, Legendre C, Kaveri SV, Thaunat O, Lacroix-Desmazes S.

PLoS One. 2013 Aug 15;8(8):e70731. doi: 10.1371/journal.pone.0070731. eCollection 2013.


CD8(+) T cells in multiple sclerosis.

Denic A, Wootla B, Rodriguez M.

Expert Opin Ther Targets. 2013 Sep;17(9):1053-66. doi: 10.1517/14728222.2013.815726. Epub 2013 Jul 6. Review.


The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.

Wootla B, Watzlawik JO, Denic A, Rodriguez M.

Expert Rev Clin Immunol. 2013 Jun;9(6):535-49. doi: 10.1586/eci.13.37. Review.


PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.

Loupy A, Ramakrishnan SK, Wootla B, Chambrey R, de la Faille R, Bourgeois S, Bruneval P, Mandet C, Christensen EI, Faure H, Cheval L, Laghmani K, Collet C, Eladari D, Dodd RH, Ruat M, Houillier P.

J Clin Invest. 2012 Sep;122(9):3355-67. doi: 10.1172/JCI57407. Epub 2012 Aug 13.


High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance.

Wittenberg NJ, Im H, Xu X, Wootla B, Watzlawik J, Warrington AE, Rodriguez M, Oh SH.

Anal Chem. 2012 Jul 17;84(14):6031-9. doi: 10.1021/ac300819a. Epub 2012 Jul 3.


Is multiple sclerosis an autoimmune disease?

Wootla B, Eriguchi M, Rodriguez M.

Autoimmune Dis. 2012;2012:969657. doi: 10.1155/2012/969657. Epub 2012 May 16.


Need for a paradigm shift in therapeutic approaches to CNS injury.

Wootla B, Denic A, Warrington AE, Rodriguez M.

Expert Rev Neurother. 2012 Apr;12(4):409-20. doi: 10.1586/ern.12.24. Review.


Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis.

Denic A, Pirko I, Wootla B, Bieber A, Macura S, Rodriguez M.

Brain Pathol. 2012 Sep;22(5):698-708. doi: 10.1111/j.1750-3639.2012.00576.x. Epub 2012 Mar 8.


Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.

Wootla B, Denic A, Keegan BM, Winters JL, Astapenko D, Warrington AE, Bieber AJ, Rodriguez M.

Neurol Res Int. 2011;2011:780712. doi: 10.1155/2011/780712. Epub 2011 Sep 22.


Autoantibodies with enzymatic properties in human autoimmune diseases.

Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M.

J Autoimmun. 2011 Sep;37(2):144-50. doi: 10.1016/j.jaut.2011.05.007. Epub 2011 May 31. Review.


Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S.

Blood. 2011 Feb 17;117(7):2257-64. doi: 10.1182/blood-2010-07-296103. Epub 2010 Dec 3.


Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.

Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Sibéril S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Lévy Y, Mouthon L, Sautès-Fridman C, Hermine O, Kaveri SV.

J Autoimmun. 2011 Feb;36(1):9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9.


Tissue kallikrein permits early renal adaptation to potassium load.

El Moghrabi S, Houillier P, Picard N, Sohet F, Wootla B, Bloch-Faure M, Leviel F, Cheval L, Frische S, Meneton P, Eladari D, Chambrey R.

Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13526-31. doi: 10.1073/pnas.0913070107. Epub 2010 Jul 12.


NHE4 is critical for the renal handling of ammonia in rodents.

Bourgeois S, Meer LV, Wootla B, Bloch-Faure M, Chambrey R, Shull GE, Gawenis LR, Houillier P.

J Clin Invest. 2010 Jun;120(6):1895-904. doi: 10.1172/JCI36581. Epub 2010 May 17.


Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.

Wootla B, Mahendra A, Dimitrov JD, Friboulet A, Borel-Derlon A, Rao DN, Uda T, Borg JY, Bayry J, Kaveri SV, Lacroix-Desmazes S.

FEBS Lett. 2009 Aug 6;583(15):2565-72. doi: 10.1016/j.febslet.2009.07.009. Epub 2009 Jul 15.


Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.

Wootla B, Rao DN, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri SV.

Clin Rev Allergy Immunol. 2009 Oct;37(2):97-104. doi: 10.1007/s12016-009-8116-3. Review. Erratum in: Clin Rev Allergy Immunol. 2009 Oct;37(2):96. Desirazu, Narasimha Rao [corrected to Rao, Desirazu Narasimha].


Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients.

Wootla B, Nicoletti A, Patey N, Dimitrov JD, Legendre C, Christophe OD, Friboulet A, Kaveri SV, Lacroix-Desmazes S, Thaunat O.

J Immunol. 2008 Jun 15;180(12):8455-60.


Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.

Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S.

J Immunol. 2008 Jun 1;180(11):7714-20.


Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.

Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repessé Y, Wootla B, Lacroix-Desmazes S.

Haemophilia. 2007 Dec;13 Suppl 5:61-4. doi: 10.1111/j.1365-2516.2007.01575.x. Review.


Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Dasgupta S, Navarrete AM, André S, Wootla B, Delignat S, Repessé Y, Bayry J, Nicoletti A, Saenko EL, d'Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2008 Jan;93(1):83-9. doi: 10.3324/haematol.11535.


Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice.

Lavigne-Lissalde G, Lacroix-Desmazes S, Wootla B, Tarrade C, Schved JF, Kaveri SV, Granier C, Villard-Saussine S.

Thromb Haemost. 2007 Jul;98(1):138-47.


A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.

Dasgupta S, Navarrete AM, Bayry J, Delignat S, Wootla B, André S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TB, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8965-70. Epub 2007 May 14.


Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.

Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV.

Immunol Lett. 2007 May 15;110(1):23-8. Epub 2007 Apr 13. Review.


VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S.

Blood. 2007 Jan 15;109(2):610-2. Epub 2006 Sep 19.


Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.

Lacroix-Desmazes S, Wootla B, Dasgupta S, Delignat S, Bayry J, Reinbolt J, Hoebeke J, Saenko E, Kazatchkine MD, Friboulet A, Christophe O, Nagaraja V, Kaveri SV.

J Immunol. 2006 Jul 15;177(2):1355-63.


Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.

Wootla B, Dasgupta S, Mallet V, Kazatchkine MD, Nagaraja V, Friboulet A, Kaveri SV, Lacroix-Desmazes S.

Blood Coagul Fibrinolysis. 2006 Jun;17(4):229-34. Review.


Pathophysiology of catalytic antibodies.

Lacroix-Desmazes S, Wootla B, Delignat S, Dasgupta S, Nagaraja V, Kazatchkine MD, Kaveri SV.

Immunol Lett. 2006 Feb 28;103(1):3-7. Epub 2005 Nov 2. Review.


Supplemental Content

Loading ...
Support Center